Can Fite Earnings Estimate

CANF Stock  USD 1.58  0.06  3.95%   
By analyzing Can Fite's earnings estimates, investors can diagnose different trends across Can Fite's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Can Fite Biopharma is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Yuan Drop
 
Covid
Can Fite is projected to generate 0.0 in earnings per share on the 31st of March 2024. Can Fite earnings estimates show analyst consensus about projected Can Fite Biopharma EPS (Earning Per Share). It derives the highest and the lowest estimates based on Can Fite's historical volatility. Many public companies, such as Can Fite, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Can Fite's earnings estimates, investors can diagnose different trends across Can Fite's analyst sentiment over time as well as compare current estimates against different timeframes. The Can Fite's current Gross Profit is estimated to increase to about 1.1 M, while Pretax Profit Margin is projected to decrease to (10.79).
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Can Fite Earnings per Share Projection vs Actual

About Can Fite Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Can Fite earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Can Fite estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Can Fite fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-158.5 M-166.4 M
Earnings Yield(0.80)(0.84)
Price Earnings Ratio(1.24)(1.31)
Price Earnings To Growth Ratio 0.02  0.02 

Currently Active Assets on Macroaxis

When determining whether Can Fite Biopharma is a strong investment it is important to analyze Can Fite's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Can Fite's future performance. For an informed investment choice regarding Can Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Can Fite. If investors know Can will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Can Fite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.60)
Quarterly Revenue Growth
(0.19)
Return On Assets
(0.57)
Return On Equity
(1.58)
The market value of Can Fite Biopharma is measured differently than its book value, which is the value of Can that is recorded on the company's balance sheet. Investors also form their own opinion of Can Fite's value that differs from its market value or its book value, called intrinsic value, which is Can Fite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Can Fite's market value can be influenced by many factors that don't directly affect Can Fite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Can Fite's value and its price as these two are different measures arrived at by different means. Investors typically determine if Can Fite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Can Fite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.